ALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of Firstโ€‘Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cemaโ€‘cel) in Patients With Large Bโ€‘cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy

Continue ReadingALPHA3: A Pivotal Phase 2 Study Evaluating the Safety and Efficacy of Firstโ€‘Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cemaโ€‘cel) in Patients With Large Bโ€‘cell Lymphoma (LBCL) and Minimal Residual Disease (MRD) After Response to Standard Therapy